These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22520065)

  • 1. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.
    Reny JL; Combescure C; Daali Y; Fontana P;
    J Thromb Haemost; 2012 Jul; 10(7):1242-51. PubMed ID: 22520065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Man M; Duvvuru S; Walker JR; Sundseth SS; Collet JP; Delaney JT; Hulot JS; Murphy SA; Paré G; Price MJ; Sibbing D; Simon T; Trenk D; Antman EM; Sabatine MS
    J Thromb Thrombolysis; 2016 Apr; 41(3):374-83. PubMed ID: 26573179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.
    Paré G; Ross S; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Fox KA; Eikelboom JW
    Circ Cardiovasc Genet; 2012 Apr; 5(2):250-6. PubMed ID: 22368149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.
    Lewis JP; Fisch AS; Ryan K; O'Connell JR; Gibson Q; Mitchell BD; Shen H; Tanner K; Horenstein RB; Pakzy R; Tantry US; Bliden KP; Gurbel PA; Shuldiner AR
    Clin Pharmacol Ther; 2011 Oct; 90(4):568-74. PubMed ID: 21881565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase-1 is a major determinant of clopidogrel efficacy.
    Bouman HJ; Schömig E; van Werkum JW; Velder J; Hackeng CM; Hirschhäuser C; Waldmann C; Schmalz HG; ten Berg JM; Taubert D
    Nat Med; 2011 Jan; 17(1):110-6. PubMed ID: 21170047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between
    Biswas M; Kali SK; Sarker AK; Sukasem C
    Expert Opin Drug Saf; 2023; 22(9):807-817. PubMed ID: 37148265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach.
    Al-Azzam SI; Alzoubi KH; Khabour OF; Nusair MB; Al-Hadidi H; Awidi A; Saleh A
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):179-86. PubMed ID: 23357840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.
    Corredor-Orlandelli D; Sambracos-Parrado S; Mantilla-García S; Tovar-Tirado J; Vega-Ramírez V; Mendoza-Ayús SD; Peña LC; Leal MF; Rodríguez-Carrillo J; León-Torres J; Pardo-Oviedo JM; Parra Abaunza K; Contreras Bravo NC; Ortega-Recalde O; Fonseca Mendoza DJ
    Vasc Health Risk Manag; 2021; 17():689-699. PubMed ID: 34764653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.
    Fontana P; James R; Barazer I; Berdagué P; Schved JF; Rebsamen M; Vuilleumier N; Reny JL
    J Thromb Haemost; 2011 Aug; 9(8):1664-6. PubMed ID: 21692977
    [No Abstract]   [Full Text] [Related]  

  • 18. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
    Peng W; Shi X; Xu X; Lin Y
    Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
    Kang YH; Lao HY; Wu H; Lai WH; Li XX; Yu XY; Chen JY; Zhong SL
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1511-9. PubMed ID: 23608957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.